Phase I Open Label Ascending Dose Study to Assess the Feasibility and Safety of Intermittent Infusions of MTX110 Administered by Convection-Enhanced Delivery (CED) in Patients With Recurrent Glioblastoma (rGBM) (MAGIC-G1)
Latest Information Update: 10 Oct 2024
Price :
$35 *
At a glance
- Drugs Panobinostat (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms MAGIC-G1
- Sponsors Biodexa Pharmaceuticals
- 04 Oct 2024 Results presented in an Biodexa Pharmaceuticals Media Release.
- 28 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2024 Results presented in a Biodexa Pharmaceuticals Media Release.